NASDAQ · CLGN
Healthcare · Biotechnology
$3.41
Up+$0.13 (+3.81%)
Updated Sep 10, 2026, 11:14 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CLGN closed at $3.41 after 20 trading sessions, up 967.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $3.51 | $3.57 | $3.30 | $3.41 | 91.06K |
| Sep 8, 2026 | $3.52 | $3.69 | $3.30 | $3.58 | 205.14K |
| Sep 4, 2026 | $3.31 | $3.91 | $2.99 | $3.55 | 237.69K |
| Sep 3, 2026 | $3.376 | $3.656 | $3.1001 | $3.412 | 209.46K |
| Sep 2, 2026 | $3.26 | $3.487 | $2.9115 | $3.433 | 287.38K |
| Sep 1, 2026 | $3.50 | $4.132 | $3.20 | $3.726 | 710.5K |
| Aug 31, 2026 | $3.80 | $9.60 | $3.61 | $3.879 | 18.27M |
| Aug 28, 2026 | $0.2891 | $0.4127 | $0.2637 | $0.358 | 8.98M |
| Aug 27, 2026 | $0.30 | $0.3079 | $0.28 | $0.2897 | 160.52K |
| Aug 26, 2026 | $0.30 | $0.3189 | $0.2905 | $0.3075 | 88.19K |
| Aug 25, 2026 | $0.33 | $0.33 | $0.2849 | $0.29 | 72K |
| Aug 24, 2026 | $0.33 | $0.33 | $0.3008 | $0.3008 | 142.3K |
| Aug 21, 2026 | $0.314 | $0.32 | $0.30 | $0.3125 | 30.87K |
| Aug 20, 2026 | $0.3078 | $0.3299 | $0.3002 | $0.3178 | 18.41K |
| Aug 19, 2026 | $0.3145 | $0.3249 | $0.3115 | $0.3218 | 16.43K |
| Aug 18, 2026 | $0.31 | $0.3148 | $0.2787 | $0.3144 | 72.31K |
| Aug 17, 2026 | $0.3003 | $0.3198 | $0.2955 | $0.3197 | 16.1K |
| Aug 14, 2026 | $0.31 | $0.3394 | $0.3001 | $0.3297 | 70.82K |
| Aug 13, 2026 | $0.3126 | $0.3276 | $0.2954 | $0.3186 | 51.18K |
| Aug 12, 2026 | $0.31 | $0.3309 | $0.2953 | $0.3193 | 62.74K |
The latest Smart Investors Daily articles mentioning CLGN.
CLGN research
Company profile and research snapshot.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 6, 2026 | D. Boral Capital | Hold | — |
| Nov 28, 2025 | D. Boral Capital | Buy | — |
| Oct 20, 2025 | D. Boral Capital | Buy | — |
| Sep 16, 2025 | D. Boral Capital | Buy | — |
| Aug 21, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 1, 2026
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) ("CollPlant" or the "Company"), today announced that its Board of Directors has approved a one-for-ten reverse share split of the Company's ordinary
Benzinga · Sep 1, 2026
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex (NASDAQ:LABT)
Benzinga · Jul 9, 2026
https://www.sec.gov/Archives/edgar/data/1631487/000121390026076733/ea0297371-f3_collplant.htm
Benzinga · Jun 30, 2026
CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CLGN.
